Citation: | LU Lan, PANG Yubing, ZHANG Yu, XUE Xiaoping. Correlation between hematological parameters and disease activity in patients with gout[J]. Journal of Clinical Medicine in Practice, 2020, 24(16): 35-38. DOI: 10.7619/jcmp.202016010 |
NEOGI T. Clinical practice of Gout [J]. N Engl J Med, 2011, 364(5): 443-52.
|
SO A, BUSSO N. Update on gout 2012[J]. Joint Bone Spine, 2012, 79(6): 539-543.
|
PUNZI L, SCANU A, SPINELLA P, et al. One year in review 2018: gout[J]. Clin Exp Rheumatol, 2019, 37(1): 1-11.
|
JENNE C N, KUBES P. Platelets in inflammation and infection[J]. Platelets, 2015, 26(4): 286-292.
|
CONWAY R, MURPHY CL, MADIGAN A, et al. Increased platelet reactivity as measured by plasma glycoprotein VI in gout[J]. Platelets, 2018, 29(8): 821-826.
|
庞雨冰, 周玮, 刘家欢, 等. 中性粒细胞/淋巴细胞与血小板/淋巴细胞比值对痛风疾病活动及治疗后病情的评估[J]. 实用医学杂志, 2018, 34(20): 3441-3444.
|
ALETAHA D, NEOGI T, SILMAN A J, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Arthritis Rheum, 2010, 62(9): 2569-2581.
|
ROBINSON P C. Gout - An update of aetiology, genetics, co-morbidities and management[J]. Maturitas, 2018, 118: 67-73.
|
HUANG W S, LIN C L, TSAI C H, et al. Association of gout with CAD and effect of antigout therapy on CVD risk among gout patients[J]. J Investig Med, 2020, 68(5): 972-979.
|
ASLAM F, MICHET C. My treatment approach to gout[J]. Mayo Clin Proc, 2017, 92(8): 1234-1247.
|
SZEKANECZ Z, SZAMOSI S, KOVÁCS GE, et al. The NLRP3 inflammasome-interleukin 1 pathway as a therapeutic target in gout[J]. Arch Biochem Biophys, 2019, 670: 82-93.
|
SO A K, MARTINON F. Inflammation in gout: mechanisms and therapeutic targets[J]. Nat Rev Rheumatol, 2017, 13(11): 639-647.
|
CHENG R, WU Z W, LI M M, et al. Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review[J]. Int J Oral Sci, 2020, 12(1): 2-10.
|
COULDWELL G, MACHLUS K R. Modulation of megakaryopoiesis and platelet production during inflammation[J]. Thromb Res, 2019, 179: 114-120.
|
BOULOS D, PROUDMAN S M, METCALF R G, et al. The neutrophil-lymphocyte ratio in early rheumatoid arthritis and its ability to predict subsequent failure of triple therapy[J]. Semin Arthritis Rheum, 2019, 49(3): 373-376.
|
HA Y J, HUR J, GO D J, et al. Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict survival in patients with adult polymyositis and dermatomyositis: A retrospective observational study[J]. PLoS One, 2018, 13(1): e0190411.
|
YAYLA M E, ÍLGEN U, OKATAN ÍE, et al. Association of simple hematological parameters with disease manifestations, activity, and severity in patients with systemic sclerosis[J]. Clin Rheumatol, 2020, 39(1): 77-83.
|
PAN L L, DU J, LI T T, et al. Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio associated with disease activity in patients with Takayasu's arteritis: a case-control study[J]. BMJ Open, 2017, 7(4): e014451.
|
SONG G G, LEE Y H. Red cell distribution width, platelet-to-lymphocyte ratio, and mean platelet volume in ankylosing spondylitis and their correlations with inflammation: a meta-analysis[J]. Mod Rheumatol, 2019: 1-6.
|
KADIYORAN C, ZENGIN O, CIZMECIOGLU H A, et al. Monocyte to Lymphocyte Ratio, Neutrophil to Lymphocyte Ratio, and Red Cell DistributionWidth are the Associates with Gouty Arthritis[J]. Acta Medica(Hradec Kralove), 2019, 62(3): 99-104.
|